Golden, Colorado—January 13, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the growing scientific support for use of stem cells that reside within the body for therapeutic and performance enhancement. A key medical advance of 2014 was research published by scientists at Stanford University and Harvard University regarding mechanisms underlying “parabiosis”, the well-known reversal of aging when young animal blood is transferred into older animals. This research, considered a key scientific advance of 2014, identified factors in blood that transform stem cells from an inactive, latent form to active cells that regenerate and replenish aging cells resulting in reversal of aging in animals . This newly identified factor, called growth-differentiation factor 11 (GDF11, or, BMP-11) adds to a growing list of endogenous biological agents that activate stem cells from quiescence to growth and differentiation. The well-known growth factors erythropoietin and G-CSF have been used as therapeutic agents for 25 years to treat anemia and immuno-suppression resulting from chemotherapy. Many stem cells exist within the body in a latent, inactive form ready to be activated by the proper molecular “switch”.
Vitro Biopharma gained proprietary technology to support development of stem cell activation methods for achieving stem cell therapy during 2014. We focused on activation of adult stem cells known as mesenchymal (MSC) and neural stem cells (NSC) that require unique signaling pathways as compared to hematopoietic stem cells. These 2014 developments by Vitro Biopharma included analysis of the activation process of MSCs and NSCs, and on enhanced understanding of the activation mechanisms necessary to activate these specific stem cells. Analysis of stem cell activation is based on biomarker profiling together with unique imaging platforms enabling clinical determination of stem cell activation.
We are now conducting trials of the clinical effects of stem cell activation in Europe through Dr. Josef Smarda and our distribution partner, Pete Shuster of Neuromics, Inc. Autistic and immuno-compromised patients show apparent improvement by stem cell activation in “proof-of-principal” studies. We plan to extend these trials to US-based studies in 2015, based on regulatory approval, that include safety/efficacy studies of traumatic brain injury (TBI), concussion and other neurodegenerative conditions. TBI affects about 1% of the population and is currently undertreated, largely by physical therapy and rehabilitation. Activation of stem cells residing within the brain may lead to regeneration of brain function as supported by pre-clinical studies and some clinical trials.
Dr. Jim Musick, Vitro Biopharma’s President & CEO, said, “The development of robust methods for stem cell activation is supported by numerous pre-clinical findings and basic research. There are numerous advantages of this approach to stem cell therapy including potential reduced costs of therapy and faster, lower cost pathways to regulatory approval. We have developed novel cell-based assays of stem cell activation involving determination of stem cell proliferation, migration, bio-molecule secretion and epigenetic reprogramming that we have applied to MSCs, neural stem cells and primary fibroblasts and CAFs. These assays provide a basis for evaluation of both stem cells and potential activation agents. We have used these assays to define critical parameters of our clinical trials that we plan to execute during 2015. We look forward to accelerated developments of our stem cell activation technology and products during 2015.”
About Vitro Biopharma
Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG; http://www.vitrobiopharma.com), owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. In 2011, Vitro Biopharma out-licensed its intellectual property related to treatment of infertility to Dr. James Posillico, a renowned expert in Assisted Reproductive Technologies. Vitro Biopharma also owns a pending patent for methods and materials related to treatment of neurological conditions by activation of neural stem cells. Vitro Biopharma’s mission is “Harnessing the Power of Cells™” for the advancement of regenerative medicine to its full potential. Vitro Biopharma operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro Biopharma manufactures and sells “Tools for Stem Cell and Drug Development™”, including human mesenchymal stem cells and derivatives, the MSC-Gro™ Brand of optimized media for MSC self-renewal and lineage-specific differentiation. In addition to our FSH patent licensee, Vitro Biopharma maintains several strategic partnerships including an alliance with Neuromics, Inc. (www.neuromics.com). Neuromics, Inc. is a primary distributor of Vitro Biopharma products and a well established manufacturer and distributor of a large variety of life science research products especially focused on cell-based assay systems. Also, Vitro Biopharma’s CEO is a consultant on an NSF grant at the City College of New York to advise Dr. Lane Gilcrest, Professor of Materials Science and Engineering, and his colleagues regarding the development of novel extracellular materials for use in self-renewal and differentiation of mesenchymal stem cells.
Vitro Biopharma received the Frost and Sullivan Technology Innovation Leadership Award for the industry sector: Stem Cell Tools and Technology in North America, 2014.
Safe Harbor Statement
Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.
Dr. James Musick
Chief Executive Officer
(303) 999-2130 Ext. 3
Source: Vitro Diagnostics, Inc.